Company Encyclopedia
View More
name
Medprin
301033.SZ
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers artificial dura matermembrane patches, craniomaxillofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a Synthetic Dural Substitute; NeoDura, a novel dural patch; Recranio, a Cranio-Maxillofacial repair system; and StypCel, an Absorbable Hemostat; Immiseal, a dural sealant system; and 3D bioprinting applications serving patients internationally.
876.46 B
301033.SZMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking21/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.41%A
    • Profit Margin30.26%A
    • Gross Margin81.39%A
  • Growth ScoreB
    • Revenue YoY21.99%A
    • Net Profit YoY49.30%B
    • Total Assets YoY13.45%B
    • Net Assets YoY13.28%B
  • Cash ScoreB
    • Cash Flow Margin330.43%C
    • OCF YoY21.99%A
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreA
    • Gearing Ratio11.04%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Medprin: Tang Ying has reduced her holdings by 0.9920%

    Medprin announced that shareholder Tang Ying reduced her holdings in the company by 665,100 shares through centralized bidding transactions from July 30, 2025, to October 27, 2025, at an average reduction price of 77.49 yuan/share, accounting for 0.9920% of the company's total share capital. Before the reduction, Tang Ying held 1.506 million shares, accounting for 2.2640%; after the reduction, she held 840,900 shares, accounting for 1.2541%. Together with the concerted actor Ye Tao, they held a total of 2.3109 million shares, accounting for 3.4465%

    Zhitong·
    SZ
    301033
    +1.18%
    Zhitong·
    SZ
    301033
    +1.18%

    Medprin released its performance for the first three quarters, with a net profit attributable to the parent company of 75.854 million yuan, an increase of 43.65%

    Medprin released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 249 million yuan, a year-on-year increase of 30.53%; net profit attributable to the parent company was 75.854 million yuan, a year-on-year increase of 43.65%; net profit excluding non-recurring gains and losses was 72.7919 million yuan, a year-on-year increase of 57.94%; basic earnings per share were 1.15 yuan

    Zhitong·
    SZ
    301033
    +1.18%
    Zhitong·
    SZ
    301033
    +1.18%

    Medprin: Plans to issue shares and pay cash to acquire assets and raise supporting funds of 134 million yuan

    Medprin announced that the company intends to issue shares and pay cash to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. at a transaction price of 335 million yuan. At the same time, the company plans to raise supporting funds of 134 million yuan from Guangzhou Yijian Medical Investment Co., Ltd., issuing a total of 2.3291 million shares at a price of 57.35 yuan per share

    Zhitong·
    SZ
    301033
    +1.18%
    Zhitong·
    SZ
    301033
    +1.18%

    Medprin disclosed the progress of the equity transaction for acquiring Yijie Medical, with uncertainties still remaining

    Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. disclosed the progress of its acquisition of 100% equity in Guangzhou Yijie Medical Technology Co., Ltd. This transaction is expected not to constitute a major asset reorganization but is classified as a related party transaction. Planning for the transaction began on May 22, 2025, and after a suspension and resumption of trading, due diligence is still ongoing, and related work has not yet been completed. The transaction requires approval from the board of directors, shareholders' meeting, and review by the Shenzhen Stock Exchange and the China Securities Regulatory Commission, which introduces uncertainty. The company will update progress in a timely manner

    Zhitong·
    SZ
    301033
    +1.18%
    Zhitong·
    SZ
    301033
    +1.18%

    Medprin: Absorbable regenerated oxidized cellulose hemostatic granules enter clinical trial phase

    According to the Zhitong Finance APP, Medprin announced that its research and development project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has recently officially entered the clinical trial stage. In surgical procedures, when ligation or other traditional hemostatic methods cannot be performed or are ineffective, this product can be used as an auxiliary hemostatic product to control capillary, venous, and small arterial bleeding

    Zhitong·
    SZ
    301033
    +1.18%
    Zhitong·
    SZ
    301033
    +1.18%
    © 2025 Longbridge｜Disclaimer